Clinical trial of Lu-177- HEDMP for bone pain palliation of bone metastasis in breast cancer

Phase 1

• Conditions: BREAST CANCER.; Malignant neoplasm of breast; C50-C50

• Registration Number: IRCT201109217611N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Severe metastatic bone pain in breast cancer; positive bone scan in recent 1 month corresponding to the painful regions ; normal recent CBC (WBC>2400/ul--Platelet>60000/UL)
Exclusion criteria: Negative bone scan ; Pathological fracture of the vertebrae ;
WBC<2400/ul---Platelet<60000/ul ; incooperative patients

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SEVERITY OF PAIN. Timepoint: every 2 weeks up to 12 weeks. Method of measurement: questionnaire-By call.

Secondary Outcome Measures

Name	Time	Method
Reduced morbidity- reduce sedative consumption. Timepoint: 12 weeks after drug administration. Method of measurement: questionnare.